Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8601317 | 1.00 | CA5A (0.43) | CA5ACA5BBLMKDM4E | |
| Sulfuric Acid SCHEMBL8520468 | 0.97 | CA5A (0.40) | CA5ACA5B | |
| Sulfuric Acid SCHEMBL16618110 | 0.97 | CA5A (0.40) | CA5ACA5B | |
| Sulfuric Acid SCHEMBL4791378 | 0.94 | CA5A (0.38) | CA5ACA5B | |
| Sulfuric Acid SCHEMBL11824871 | 0.93 | CA5A (0.43) | CA5ACA5BBLMKDM4E | |
| Sulfuric Acid SCHEMBL2512992 | 0.89 | — | — | |
| Sulfuric Acid SCHEMBL17672948 | 0.85 | CA5A (0.50) | CA5ACA5BBLMKDM4E | |
| Sulfuric Acid SCHEMBL13280458 | 0.82 | — | — | |
| Sulfuric Acid SCHEMBL2547472 | 0.80 | — | — | |
| Ether SCHEMBL10415713 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062723-A | Preparation method of thiabendazole intermediate | 帕潘纳(北京)科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| CN-112062723-B | Preparation method of thiabendazole intermediate | 帕潘纳(北京)科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111755735-B | Porous organic compound electrolyte and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2021-12-14 | — | — | CN | disclosed |
| CN-112062723-A | Preparation method of thiabendazole intermediate | 帕潘纳(北京)科技有限公司 | 2020-12-11 | — | — | CN | disclosed |
| CN-111755735-A | Porous organic compound electrolyte and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2020-10-09 | — | — | CN | disclosed |
| EP-2762485-B1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | GLYTECH INC (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-2684899-B1 | METHOD FOR PRODUCING GLYCOPEPTIDE HAVING SIALYL SUGAR CHAIN, SIALYL SUGAR CHAIN-ADDED AMINO ACID DERIVATIVE TO BE USED IN SAME, AND GLYCOPEPTIDE | GLYTECH INC (JP) | 2018-04-25 | — | — | EP | disclosed |
| CN-103534276-B | There is the manufacture method of the glycopeptide of sialic acid sugar chain, for the sialic acid sugar chain addition amino acid derivative of this manufacture method and this glycopeptide | GLYTECH, INC. (JP) | 2016-03-02 | — | — | CN | disclosed |
| US-9073978-B2 | Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide | GLYTECH, INC. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20140377807-A1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | GLYTECH, INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| CN-1237171-A | Substituted benzocycloheptapyridine derivatives useful as farnesyl protein transferase inhibitors | SCHERING CORP (US) | 1999-12-01 | — | — | CN | disclosed |
| CN-1237165-A | Tricyclic inhibitors of farnesyl protein transferase | SCHERING CORP (US) | 1999-12-01 | — | — | CN | disclosed |
| CN-1236364-A | Substituted benzocycloheptapyridine derivatives useful for inhibition of Farnesyl protein transferase | SCHERING CORP (US) | 1999-11-24 | — | — | CN | disclosed |
| WO-1998049163-A1 | COMPLEX COMPRISING A RARE-EARTH METAL ION AND A COMPLEXING MOIETY | AKZO NOBEL N.V. (NL) | 1998-11-05 | — | — | WO | disclosed |
| US-5770456-A | Cyclic nucleic acid and polypeptide arrays | AFFYMETRIX, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1997015566-A1 | NOVEL OLIGOMERS, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE | GEORGHIOU PARIS E (CA) | 1997-05-01 | — | — | WO | disclosed |
| US-5550215-A | FORMING POLYMER ON SUBSTRATE WITH A TETHER MOLECULE; CYCLIZATION; DEPROTECTING; DECYCLIZATION | AFFYMETRIX, INC. | 1996-08-27 | — | — | US | disclosed |
| US-5527681-A | Immobilized molecular synthesis of systematically substituted compounds | AFFYMAX TECHNOLOGIES N.V. (NL) | 1996-06-18 | — | — | US | disclosed |
| WO-1993010161-A1 | POLYMER REVERSAL ON SOLID SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-05-27 | — | — | WO | disclosed |
| US-4465567-A | Process for the manufacture of 3-hydroxy-2-cycloalken-1-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 1984-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377807-A1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | MET, NCLN, LNPEP | CA5A 3601/4885CA5B 3130/4885BLM 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.